SOLIGENIX, INC. Notes Payable, Current
SOLIGENIX, INC. (SNGX) had Notes Payable, Current of $394.62 thousand as of 2021-03-31, per its 10-Q filed 2021-05-18.
Discontinued › Balance Sheet › Liabilities › Liabilities, Current › Long-Term Debt and Lease Obligation, Current
us-gaap:NotesPayableCurrent · last filed 2022-03-29
- 2021-03-31: Notes Payable, Current $394.62K.
- 2020-12-31: Notes Payable, Current $324.98K.
- 2020-09-30: Notes Payable, Current $255.34K.
- 2020-06-30: Notes Payable, Current $185.70K.
| Period end | Notes Payable, Current |
|---|---|
| 2021-03-31 | $394.62K 10-Q · filed 2021-05-18 |
| 2020-12-31 | $324.98K 10-K · filed 2022-03-29 |
| 2020-09-30 | $255.34K 10-Q · filed 2020-11-12 |
| 2020-06-30 | $185.70K 10-Q · filed 2020-08-14 |
| 2016-03-31 | $298.97K 10-Q · filed 2016-05-12 |
| 2015-12-31 | $292.72K 10-K · filed 2017-03-27 |
| 2015-09-30 | $286.40K 10-Q · filed 2015-11-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Imunon, Inc. (IMNN) | United States | $0.008B | -0.56 |
| EXICURE, INC. (XCUR) | United States | $0.008B | -1.54 |
| Traws Pharma, Inc. (TRAW) | United States | $0.009B | -0.58 |
| Alzamend Neuro, Inc. (ALZN) | United States | $0.009B | |
| Ensysce Biosciences, Inc. (ENSC) | United States | $0.008B | -0.37 |
| InMed Pharmaceuticals Inc. (INM) | $0.008B | -0.65 | |
| Apimeds Pharmaceuticals US, Inc. (APUS) | United States | $0.008B | |
| FibroBiologics, Inc. (FBLG) | United States | $0.009B | -0.27 |
| CNS Pharmaceuticals, Inc. (CNSP) | United States | $0.007B | |
| Acurx Pharmaceuticals, Inc. (ACXP) | United States | $0.007B | -0.97 |